Loading...

LENZ LENZ THERAPEUTICS INC Other Situations 8-K Filing

LNZ

LNZ

LENZ THERAPEUTICS INC

(LENZ)

2023 8-K

Show Summary

Show Summary

Earnings Releases

Financial Update

Financial Results

Financial Results

Clinical Trial Data

Financial Results

FDA Application

Private Placement

Earnings Reports

Press Release and Corporate...

Merger Agreement and Name C...

Merger Agreement

Dividend Announcement

Merger Agreement

Merger Agreement

Merger Agreement

Sublease Agreement

Appointment and Restructuring

Appointment of Director

Resignation of CFO

Earnings Reports

Retention Agreements

Costs Associated with Exit ...

Announcement of Voluntary P...

External Links:

Graphite Bio announces voluntary pause of Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease.

AI Assistant

LENZ THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.